Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
| Ticker |
BMRN
|
| CIK | 0001048477 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 105 DIGITAL DRIVE, NOVATO, CA, 94949 |
| Website | biomarin.com |
| Phone | 4155066700 |
| CEO | Jean-Jacques Bienaimé |
| Employees | 3,080 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid ChoiceBioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a BetThe consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics StocksAs the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |